Paediatric Multisystem Inflammatory Syndrome Associated with COVID-19 Infection: A Case Series
Published: September 1, 2021 | DOI: https://doi.org/10.7860/JCDR/2021/49495.15332
Aneesha Mathew, Akshay K Nair, Harish Kumar, Renoy Phillip, Rini Susan Varghese
1. Student, Department of Pharmacy, K.L.E College of Pharmacy, Bangalore, Karnataka, India.
2. Student, Department of Pharmacy, K.L.E College of Pharmacy, Bangalore, Karnataka, India.
3. Paediatric Intensivist, Department of Paediatrics, Aster CMI Hospital, Bangalore, Karnataka, India.
4. Clinical Pharmacist, Department of Pharmacy Practice, Aster CMI Hospital, Bangalore, Karnataka, India.
5. Assistant Professor, Department of Pharmacy Practice, K.L.E College of Pharmacy, Bangalore, Karnataka, India.
Correspondence
Dr. Akshay K Nair,
Kuzhippillil House, Kottiyoor P.O, Panniyamala, Iritty (taluk), Kannur, Kerala, India.
E-mail: akshayknair5000@gmail.com
Multisystem Inflammatory Syndrome (MIS) is a newer, rarer and dangerous childhood disease that require early attention and is associated with Coronavirus Disease-2019 (COVID-19) infection. This article reports four clinically ill children of age 6-15 years admitted to Aster CMI Hospital, Bengaluru, Karnataka, India, during October and November 2020. The diagnosis was based on elevated laboratory values (D-Dimer, C-Reactive Protein (CRP), and Ferritin) and positive COVID-19 antibody test. No infectious aetiologies were identified. All patients presented at Emergency Room (ER) with hypotensive shock and were treated with inotropic support, Intravenous Immunoglobulin (IVIg), and steroids. Children responded well to treatment and were discharged within a period of 8-11 days. Clinical characteristics are necessary for understanding more about newly identified paediatric illness.
[
FULL TEXT ] | [ PDF]